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Abstract 
BACKGROUND: Eruptive xanthomas are rare and often asymptomatic. On the other hand, these cutaneous 
lesions are a red flag for serious underlying metabolic disorders that demand an early diagnosis to prevent 
morbidity and mortality. 
CASE REPORT: We report on two male patients, aged 23 and 27 years, who presented with eruptive xanthomas. 
Clinical, histological and laboratory investigations disclosed a metabolic syndrome in the younger patient and an 
alcohol-induced chylomicronemia in the elder one. Two types of macromorphology of cutaneous lesions were 
observed. Treatment was tailored according to underlying pathologies and resulted in significant improvement of 
the metabolic parameters and improvement of skin lesions. 
CONCLUSION: Dermatologists should be aware of the diagnostic importance of eruptive xanthomas for serious 
metabolic disorders. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Xanthomas are cutaneous lesions developing 
as a result of local storage of lipids. Xanthomas can 
be classified according to the clinical presentation of 
the individual lesion or by the mode of appearance. 
Eruptive xanthomas are uncommon and represent an 
important clinical sign for serious metabolic disorders. 
Low-density lipoprotein particles are preferably stored 
in foam cells and giant cells [1]. A particular subtype is 
neutrophilic eruptive xanthomas, mostly but not 
exclusively seen in cases of immunosuppression or 
immunodeficiency [2].  
Clinically, the lesions appear as rapidly 
evolving papules with a red-to-yellowish hue and are 
about 1-5 mm in diameter. They generally form across 
the extensor surfaces of the arms and legs, as well as 
across the buttocks, and may involve palmoplantar 
skin along the creases. The lesions can be tender, 
often they remain asymptomatic, but early lesions 
may be pruritic. Eruptive xanthomas may be 
associated with diabetes mellitus, 
hypercholesterolemia, hypertriglyceridemia, lipemia 
retinalis, or hepatosteatosis [3], [4]. Another but 
unusual cause is tattooing that causes a Koebner 
phenomenon [5], [6]. The recognition of underlying 
metabolic disorders is necessary to prevent 
conceivable fatal medical conditions such as coronary 
artery disease or pancreatitis [7]. 
 
 
Case reports 
 
Case 1: A 23-year-old male presented with 
multiple non-pruriginous papules, that developed 
during five years. He was a heavy cigarette smoker 
without alcohol abuse. His medical history was 
remarkable for acute pancreatitis one year before of 
unknown cause. His father died from myocardial 
infarction. 
On examination, we found an obese male 
patient with a body-mass-index of 35.9. He had 
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disseminated reddish to yellowish papules of variable 
diameter (from several millimetres to 1 cm) arranged 
in stripes on his trunk and the extremities (Figure 1). 
Predominant sites were the neck, lower back, 
buttocks, palmar area, and the extension sites of the 
arms. 
 
Figure 1: Eruptive xanthomas with unrecognised metabolic 
syndrome; a) Multiple papules on the buttocks and lower back; b) 
extension sites of the arms and c) palms 
 
We took a biopsy for histopathological 
examination. The investigations revealed foam cells 
and some Touton giant cells in the upper dermis. The 
foam cells were CD68 positive, while stains for S100 
and CD1a remained negative (Figure 2). The 
diagnosis of xanthomas was made. 
 
Figure 2: Histology of eruptive xanthomas; a) Hematoxylin-eosin 
stain with foam cells of the upper dermis; b) Positive staining for 
CD68 (Original magnification x 4) 
 
Laboratory investigations: Blood glucose 16.7 
mmol/l; HbA1c 11.6 % (normal range 4-6); cholesterol 
16.5 mmol/l (normal range < 5.2); triglycerides 4.66 
mmol/l (< 2.3), very low-density lipoprotein (VLDL) 
was extremely increased. Blood cell counts, liver 
enzymes, lipoprotein (a), and clotting parameters 
were in the normal range. Blood serum was lipemic 
(Figure 3). 
 
Figure 3: Lipemic serum (right) versus normal serum (left) 
 
Imaging: X-ray of the chest and ultrasound of 
the abdomen were unremarkable. Repeated blood 
pressure measurements revealed hypertension. The 
patient was treated by an interdisciplinary approach 
for diabetes mellitus type II and hyperlipidemia. We 
started with subcutaneous insulin and certoparin 
injections to stimulate the lipoprotein lipase. After 
significant improvement of the glucose metabolism, 
the treatment was switched to combined oral 
medication of metformin and sitagliptin. The 
hypertension was treated with oral ramipril. We also 
recommended a low-lipid diet. At the end of his 
hospital stay, blood glucose was 5.7 mmol/l and 
cholesterol 3.67 mmol/l. The cutaneous lesion started 
to diminish. 
 
Case 2: A 27-year-old male presented with 
multiple, moderate pruritic cutaneous plane yellowish 
plaques which developed throughout 2 weeks. His 
medical history was positive for pollinosis and nodular 
struma. The family history disclosed no risk factors for 
cardiovascular or cutaneous disorders. He had regular 
alcohol consume. 
On examination, we observed an otherwise 
healthy non-obese male patient with disseminated 
yellowish plane cutaneous lesions on trunk and flexion 
sites of extremities (Figure 4). Palms, soles and face 
were spared. 
 
Figure 4: Eruptive xanthomas with chylomicronemia; a) Flat 
yellowish plaques; b) Dermoscopy with polarised light 
(Dermogenius) demonstrating structureless plaque without 
erythema or vascular proliferation 
 
We took a skin biopsy. Histopathologic 
examination revealed lipid storing macrophages in the 
upper and mid-dermis, foam cells were absent. 
Infiltrates composed of lymphocytes and mast cells 
with some intermingled neutrophils and eosinophils 
were localised perivascular. The macrophages were 
CD 68-positive but lacked S-100 or CD1a. The 
diagnosis of eruptive xanthomas was confirmed. 
Laboratory investigations: Triglycerides 9.84 
mmol/l (normal range < 2.3); cholesterol 15.94 mmol/l 
(normal range < 5.2); lipoprotein (a) 0.74 g/l (normal 
range < 0.3); triglyceride/ cholesterol ratio 12.62 
(normal range < 1.5); gamma-glutamyl transferase 
6.66 µkat/l (normal range < 1). Liver transaminases 
and eosinophil count were slightly increased. Blood 
glucose levels and pancreatic lipase were in the 
normal range. Imaging: Chest-X-ray and abdominal 
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ultrasound unremarkable. The diagnosis of an 
alcohol-induced chylomicronemia with eruptive 
xanthomas was made. A reduction of alcohol 
consumption was recommended what significantly 
reduced hyperlipidemia. In the interdisciplinary 
consultation, medical drug therapy was not 
recommended since the reduction or avoidance of 
substance abuse leads to normalisation. There was 
no clue for familial chylomicronemia syndrome. 
 
 
Discussion 
 
Eruptive xanthomas may be the result of a 
variety of metabolic disorders, medical drugs 
(glucocorticoids, retinoids, estrogens), secondary 
insulin resistance, and alcohol abuse. The most 
common causes represent chylomicronemia and 
hypertriglyceridemia either due to lipoprotein lipase 
deficiency (Type I hyperlipoproteinemia) or familial 
hyperlipoproteinemia (Type V hyperlipoproteinemia). 
In diabetic patients unresponsive to insulin, an 
acquired lipoprotein lipase deficiency may develop [8]. 
Rare syndromes associated with eruptive xanthomas 
are the Berardinelli-Seip syndrome [9], the von Gierke 
syndrome (glycogen storage disease type I) [10], or 
the primary lipoprotein-lipase deficiency [11]. 
LDL is one of the major carriers of cholesterol. 
Circulating LDL particles in the blood stream realise 
the cholesterol transport to those cells that are 
requiring lipids. These cells express higher levels of 
the LDL-receptor (LDLR) that mediates uptake of LDL 
particles by receptor-mediated endocytosis. For plane 
xanthomas, development of foam cells is associated 
with the uptake of LDL particles that are modified due 
to increased residence time in plasma by over-
expressed macrophage scavenger receptor (SR) [12]. 
Sortilin, a transmembrane receptor expressed by 
macrophages that binds LDL and support intracellular 
LDL uptake, is another driver for their transformation 
into foam cell [13]. In eruptive xanthomas, foam cells 
may develop due to inflammatory stress. Thereby, 
LDL receptor negative feedback regulation induced by 
intracellular cholesterol becomes disrupted [14]. 
We presented two young male patients with 
eruptive xanthomas with a slightly different clinical 
appearance of the cutaneous lesions. In case # 1 the 
lesions were reddish to yellowish papules with a 
preference of the extension sites of the arms. The 
underlying pathology was an unrecognised metabolic 
syndrome. In case # 2, the lesions were flat, moderate 
pruritic, yellowish without an erythematous note and 
preferred the flexion sites of the arms. The underlying 
pathology was alcohol-induced chylomicronemia. The 
treatment was tailored according to the individual 
needs. Diagnosis of underlying metabolic disorders 
and their correction by treatment is an appropriate 
method to improve eruptive xanthomas.  
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